According to dozens of annual reports submitted by pharmaceutical companies to the Securities and Stock Exchange in late February, the budget and decline in staff in the Food and Drug Administration conducted by President Donald Trump Orchestra by President Donald Trump could prevent new or commercial production of new drugs.
“The Trump administration has approved several executive measures that can impose significant burden, or otherwise delayed the FDA’s ability to supervise and regulatory activities,” said one of the Pharmacyuticals cases, a Canadian -based company that epilepsy. “If these implementation measures impose restrictions on FDA’s ability to participate in supervision and implementation activities in the normal course, our business may have a negative impact.”
In February, the so -called Foreign Ministry Elvan’s efficiency fired hundreds of FDA employees, causing widespread terror over the status of grant programs, active clinical tests and drug approvals. Only more than a week later, a few employees who regulate the supply of US food and examine medical supplies again obtained.
This has done little to alleviate concerns about various pharmaceutical companies, which are concerned that any slow -moving bureaucracy can cause the FDA to stop. Before new drugs can be marketed, the FDA has to conduct regular inspections, a process that can take years. Many recent SEC files say that if the FDA stops this, these drugs are simply not published.
Rezolute, which provides treatments for a rare and congenital low blood sugar form, says the DOGE task for “reducing spending” in agencies such as the FDA slows them. “Our trade depends on the FDA and the FDA’s ability to respond timely to drug development activities,” the company adds.
Some pharmaceutical companies at the National Institute of Health have provided tens of billions of dollars for drug research and development for companies and universities around the world.
In a recent case, a health care company, a health care company, said in a recent case that DOGE is creating “pressures and uncertainty” about the federal budget, including a debt ceiling that claims “may have a negative impact on the economic environment, limit the costs of health care and health care.”
Some cases have also warned of the possibility that Trump will repair existing drugs, which will be an additional cost and cost to comply. A recent Trump guideline has issued extensive deregulation regulations in federal agencies, and new Minister of Health and Human Services Robert F. Kennedy has expressed an agreement and proposed a reduction in his budget.
DOGE recently frozen $ 1.5 billion for medical research, then destroyed some budgets later. Launch and lagging companies are unclear whether the US government can ultimately expect the US government to support its research. Ibio, a company based in San Diego, studied antibody treatment for obesity and cardiac and metabolic disorders, said in a case that he is currently “unknown” how Trump’s health care policy affects its research budget.
